Terns Total Stockholder Equity vs Short Term Investments Analysis

TERN Stock

USD 6.26 0.36 6.10%

Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Total Stockholder Equity and its Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

Total Stockholder Equity vs Short Term Investments

Total Stockholder Equity vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Total Stockholder Equity account and Short Term Investments. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Terns Pharmaceuticals' Total Stockholder Equity and Short Term Investments is 0.86. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Total Stockholder Equity and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Terns Pharmaceuticals are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Total Stockholder Equity i.e., Terns Pharmaceuticals' Total Stockholder Equity and Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Term Investments

Short Term Investments is an item under the current assets section of Terns Pharmaceuticals balance sheet. It contains any investments Terns Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Terns Pharmaceuticals can easily liquidate in the marketplace.

Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 20th of May 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.

	2021	2022	2023	2024 (projected)
Interest Income	170K	2.1M	12.9M	13.5M
Net Interest Income	170K	2.1M	12.9M	13.5M

Interest Income Net Interest Income

Terns Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.82	0.71	0.56	0.47	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88	1.0	-0.78	1.0
Other Current Liab	0.66		0.92	0.64	0.94	0.58	0.88	-0.01	-0.87	0.69	0.07	0.78	-0.58	-0.61	0.62	0.64	0.7	-0.93	0.7	0.71	-0.2	0.57	0.84	0.66	-0.33	0.6
Total Current Liabilities	0.38	0.92		0.35	0.75	0.27	0.7	0.09	-0.63	0.39	0.01	0.65	-0.43	-0.44	0.33	0.41	0.41	-0.81	0.46	0.44	0.14	0.26	0.57	0.38	0.04	0.3
Total Stockholder Equity	1.0	0.64	0.35		0.74	0.9	0.69	-0.56	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.75	0.86	-0.75	0.76	0.88	-0.74	0.93	0.88	1.0	-0.79	1.0
Other Liab	0.75	0.94	0.75	0.74		0.71	0.93	0.02	-0.92	0.86	0.01	0.83	-0.58	-0.61	0.73	0.69	0.81	-0.92	0.74	0.78	-0.44	0.71	0.95	0.75	-0.56	0.71
Net Tangible Assets	0.9	0.58	0.27	0.9	0.71		0.63	-0.39	-0.89	0.8	0.35	0.46	-0.81	-0.84	0.9	0.74	0.98	-0.73	0.92	0.96	-0.82	0.99	0.84	0.9	-0.92	0.9
Property Plant And Equipment Net	0.69	0.88	0.7	0.69	0.93	0.63		-0.11	-0.83	0.7	0.15	0.95	-0.51	-0.52	0.67	0.47	0.72	-0.86	0.64	0.74	-0.4	0.66	0.92	0.69	-0.5	0.65
Net Debt	-0.57	-0.01	0.09	-0.56	0.02	-0.39	-0.11		0.12	0.15	-0.99	0.09	0.59	0.56	-0.58	-0.17	-0.24	0.13	-0.2	-0.36	0.34	-0.44	-0.21	-0.57	0.27	-0.59
Retained Earnings	-0.82	-0.87	-0.63	-0.81	-0.92	-0.89	-0.83	0.12		-0.88	-0.12	-0.72	0.7	0.75	-0.8	-0.79	-0.96	0.9	-0.94	-0.95	0.55	-0.87	-0.92	-0.81	0.72	-0.79
Accounts Payable	0.71	0.69	0.39	0.71	0.86	0.8	0.7	0.15	-0.88		-0.18	0.62	-0.5	-0.54	0.71	0.77	0.87	-0.73	0.8	0.79	-0.65	0.78	0.86	0.71	-0.8	0.7
Cash	0.56	0.07	0.01	0.56	0.01	0.35	0.15	-0.99	-0.12	-0.18		-0.06	-0.59	-0.56	0.57	0.16	0.21	-0.17	0.18	0.34	-0.27	0.4	0.22	0.56	-0.2	0.58
Non Current Assets Total	0.47	0.78	0.65	0.46	0.83	0.46	0.95	0.09	-0.72	0.62	-0.06		-0.23	-0.25	0.44	0.33	0.57	-0.71	0.53	0.6	-0.22	0.48	0.79	0.46	-0.36	0.42
Non Currrent Assets Other	-0.86	-0.58	-0.43	-0.86	-0.58	-0.81	-0.51	0.59	0.7	-0.5	-0.59	-0.23		1.0	-0.86	-0.55	-0.78	0.78	-0.68	-0.76	0.68	-0.83	-0.7	-0.86	0.64	-0.85
Other Assets	-0.87	-0.61	-0.44	-0.87	-0.61	-0.84	-0.52	0.56	0.75	-0.54	-0.56	-0.25	1.0		-0.86	-0.6	-0.82	0.79	-0.73	-0.8	0.67	-0.85	-0.71	-0.87	0.66	-0.86
Cash And Short Term Investments	1.0	0.62	0.33	1.0	0.73	0.9	0.67	-0.58	-0.8	0.71	0.57	0.44	-0.86	-0.86		0.75	0.86	-0.73	0.76	0.88	-0.75	0.93	0.87	1.0	-0.8	1.0
Common Stock Shares Outstanding	0.76	0.64	0.41	0.75	0.69	0.74	0.47	-0.17	-0.79	0.77	0.16	0.33	-0.55	-0.6	0.75		0.77	-0.58	0.84	0.8	-0.37	0.71	0.67	0.76	-0.6	0.75
Short Term Investments	0.86	0.7	0.41	0.86	0.81	0.98	0.72	-0.24	-0.96	0.87	0.21	0.57	-0.78	-0.82	0.86	0.77		-0.81	0.95	0.97	-0.75	0.97	0.89	0.86	-0.88	0.85
Non Current Liabilities Total	-0.76	-0.93	-0.81	-0.75	-0.92	-0.73	-0.86	0.13	0.9	-0.73	-0.17	-0.71	0.78	0.79	-0.73	-0.58	-0.81		-0.73	-0.78	0.47	-0.73	-0.89	-0.76	0.52	-0.72
Other Current Assets	0.77	0.7	0.46	0.76	0.74	0.92	0.64	-0.2	-0.94	0.8	0.18	0.53	-0.68	-0.73	0.76	0.84	0.95	-0.73		0.97	-0.54	0.88	0.77	0.77	-0.75	0.75
Other Stockholder Equity	0.88	0.71	0.44	0.88	0.78	0.96	0.74	-0.36	-0.95	0.79	0.34	0.6	-0.76	-0.8	0.88	0.8	0.97	-0.78	0.97		-0.65	0.95	0.87	0.88	-0.82	0.87
Total Liab	-0.72	-0.2	0.14	-0.74	-0.44	-0.82	-0.4	0.34	0.55	-0.65	-0.27	-0.22	0.68	0.67	-0.75	-0.37	-0.75	0.47	-0.54	-0.65		-0.85	-0.65	-0.72	0.94	-0.75
Net Invested Capital	0.92	0.57	0.26	0.93	0.71	0.99	0.66	-0.44	-0.87	0.78	0.4	0.48	-0.83	-0.85	0.93	0.71	0.97	-0.73	0.88	0.95	-0.85		0.86	0.92	-0.93	0.93
Property Plant And Equipment Gross	0.88	0.84	0.57	0.88	0.95	0.84	0.92	-0.21	-0.92	0.86	0.22	0.79	-0.7	-0.71	0.87	0.67	0.89	-0.89	0.77	0.87	-0.65	0.86		0.88	-0.74	0.86
Total Current Assets	1.0	0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88		-0.78	1.0
Capital Stock	-0.78	-0.33	0.04	-0.79	-0.56	-0.92	-0.5	0.27	0.72	-0.8	-0.2	-0.36	0.64	0.66	-0.8	-0.6	-0.88	0.52	-0.75	-0.82	0.94	-0.93	-0.74	-0.78		-0.8
Net Working Capital	1.0	0.6	0.3	1.0	0.71	0.9	0.65	-0.59	-0.79	0.7	0.58	0.42	-0.85	-0.86	1.0	0.75	0.85	-0.72	0.75	0.87	-0.75	0.93	0.86	1.0	-0.8

Click cells to compare fundamentals

Terns Pharmaceuticals Account Relationship Matchups

Terns Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Other Current Liab	3.3M	8.2M	4.7M	6.2M	7.6M	5.8M
Total Current Liabilities	5.0M	22.8M	6.8M	8.5M	11.9M	10.5M
Total Stockholder Equity	4.2M	68.6M	160.3M	276.9M	255.4M	153.6M
Other Liab	630K	877K	947K	1.1M	1.2M	806.7K
Net Tangible Assets	(90.8M)	(117.4M)	172.2M	276.9M	318.5M	334.4M
Property Plant And Equipment Net	961K	1.2M	1.0M	1.8M	1.0M	1.2M
Net Debt	(12.3M)	(62.0M)	(47.7M)	(142.0M)	(79.3M)	(83.3M)
Retained Earnings	(91.9M)	(131.9M)	(182.1M)	(242.4M)	(332.6M)	(316.0M)
Accounts Payable	1.6M	935K	2.1M	1.6M	2.5M	1.8M
Cash	12.3M	74.9M	47.7M	143.2M	79.9M	80.8M
Non Current Assets Total	1.7M	1.4M	1.1M	1.8M	1.1M	1.4M
Non Currrent Assets Other	719K	246K	94K	37K	56K	53.2K
Other Assets	719K	246K	94K	37K	1.0	0.95
Cash And Short Term Investments	19.7M	74.9M	166.0M	283.1M	263.4M	163.9M
Common Stock Shares Outstanding	25.1M	25.1M	25.3M	36.0M	71.3M	37.9M
Short Term Investments	7.3M	0.0	118.3M	139.9M	183.5M	192.7M
Liabilities And Stockholders Equity	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Non Current Liabilities Total	14.7M	877K	947K	1.6M	1.2M	1.1M
Other Current Assets	461K	331K	948K	2.1M	4.0M	4.2M
Other Stockholder Equity	1.2M	14.6M	174.6M	520.2M	588.0M	617.4M
Total Liab	19.7M	23.7M	7.8M	10.1M	13.2M	12.2M
Net Invested Capital	(90.8M)	(104.6M)	160.3M	276.9M	255.4M	268.1M
Property Plant And Equipment Gross	961K	1.2M	2.2M	3.2M	2.6M	1.9M
Total Current Assets	22.2M	90.9M	166.9M	285.2M	267.4M	168.9M
Accumulated Other Comprehensive Income	(106K)	(124K)	(338K)	(822K)	(19K)	(20.0K)
Net Working Capital	17.3M	68.0M	160.1M	276.7M	255.5M	158.4M
Property Plant Equipment	961K	1.2M	1.0M	757K	870.6K	924K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:

How To Invest In Terns

Details

Is Terns Stock a good investment?

Details

What is Terns Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Terns Stock analysis

When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Stocks Directory Find actively traded stocks across global markets

Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.26)

Revenue Per Share

0.035

Return On Assets

(0.24)

Return On Equity

(0.35)

The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Terns Total Stockholder Equity vs Short Term Investments Analysis

Total Stockholder Equity vs Short Term Investments

Total Stockholder Equity vs Short Term Investments Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Short Term Investments

Terns Pharmaceuticals fundamental ratios Correlations

Terns Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Terns Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Terns Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Short Term Investments	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Other Current Assets	- 0.94	Retained Earnings
Capital Stock	- 0.93	Net Invested Capital
Non Current Liabilities Total	- 0.93	Other Current Liab